Management of Dyslipidemia in Patients with Diabetes Mellitus DOI Open Access
Kyung Ae Lee

Journal of Korean Diabetes, Journal Year: 2023, Volume and Issue: 24(3), P. 111 - 119

Published: Sept. 30, 2023

Most patients with diabetes mellitus (DM) have dyslipidemia, which is characterized by increased triglycerides, decreased high-density lipoprotein cholesterol, and small dense low-density cholesterol (LDL-C). Dyslipidemia an important modifiable risk factor for cardiovascular disease (CVD). Therefore active management essential. Despite its increasing prevalence, the proportion of adequately-controlled dyslipidemia small, efforts to improve this pattern are required. The Korean Diabetes Association guidelines recommend setting goals evaluating each patient’s future CVD risk, including presence or absence CVD, target organ damage, major factors, duration DM. primary LDL-C level below 55 mg/dL (and a reduction in 50% more from baseline), 70 mg/dL, 100 highest group lowest group, respectively. Statins first-line drug choice, if not reached maximum tolerable dose statin, combination therapy ezetimibe proprotein convertase subtilisin/kexin type 9 inhibitors recommended. In hypertriglyceridemia, lifestyle changes weight loss abstinence alcohol very important, along glycemic control.

Language: Английский

2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association DOI Creative Commons
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon

et al.

Diabetes & Metabolism Journal, Journal Year: 2023, Volume and Issue: 47(5), P. 575 - 594

Published: Sept. 26, 2023

In May 2023, the Committee of Clinical Practice Guidelines Korean Diabetes Association published revised clinical practice guidelines for adults with diabetes and prediabetes. We incorporated latest research findings through a comprehensive systematic literature review applied them in manner suitable population. These are designed all healthcare providers nationwide, including physicians, experts, certified educators who manage patients or individuals at risk developing diabetes. Based on recent changes international results epidemiological study, recommended age screening has been lowered. collaboration relevant medical societies, recently managing hypertension dyslipidemia have into this guideline. An abridgment containing practical information patient education management clinic was separately.

Language: Английский

Citations

79
Dyslipidemia Fact Sheet in South Korea, 2022 DOI Creative Commons
Eun‐Sun Jin, Jee‐Seon Shim, Sung Eun Kim

et al.

Journal of Lipid and Atherosclerosis, Journal Year: 2023, Volume and Issue: 12(3), P. 237 - 237

Published: Jan. 1, 2023

This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by Society Lipid Atherosclerosis under name Dyslipidemia Fact Sheet 2022.We analyzed lipid profiles, age-standardized crude prevalence, hypercholesterolemia dyslipidemia, health behaviors adults aged ≥20 years, using Korea National Health Nutrition Examination Survey data between 2007 2020.In Korea, (total cholesterol ≥240 mg/dL or use a lipid-lowering drug) in 2020 was 24%, more than doubled from 2020. The treatment rate 55.2%, control 47.7%. (more one out three conditions [low-density lipoprotein-cholesterol ≥160 drug, triglycerides ≥200, high-density (men women) <40 mg/dL]) 40.2% 2016 However, it increased 48.2% when definition hypo-high-density lipoprotein-cholesterolemia women changed <50 mg/dL.Although has steadily remains low. Therefore, continuous efforts are needed manage through cooperation national healthcare system, patients, providers.

Language: Английский

Citations

24
Dyslipidemia Fact Sheet in South Korea, 2022 DOI Creative Commons
Eun‐Sun Jin, Jee‐Seon Shim, Sung Eun Kim

et al.

Diabetes & Metabolism Journal, Journal Year: 2023, Volume and Issue: 47(5), P. 632 - 642

Published: Aug. 2, 2023

This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by Society Lipid Atherosclerosis under name Dyslipidemia Fact Sheet 2022.

Language: Английский

Citations

19
Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review DOI Creative Commons
Chaicharn Deerochanawong, Sin Gon Kim,

Yu-Cheng Chang

et al.

Diabetes & Metabolism Journal, Journal Year: 2024, Volume and Issue: 48(2), P. 184 - 195

Published: Jan. 26, 2024

Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible hypertriglyceridemia than other ethnicities. Fenofibrate regulates hypertriglyceridemia, raises HDL-C levels, is a recommended treatment for dyslipidemia. However, data on fenofibrate use across different regions limited. This narrative review summarizes the efficacy safety of in with dyslipidemia related comorbidities (diabetes, metabolic syndrome, diabetic retinopathy, nephropathy). Long-term resulted fewer (CV) events reduced composite heart failure hospitalizations or CV mortality type 2 diabetes mellitus. plays significant role improving irisin resistance microalbuminuria, inhibiting inflammatory responses, reducing retinopathy incidence. plus combination significantly risk patients syndrome demonstrated triglyceride increased levels an acceptable profile those high ASCVD Nevertheless, care necessary due possible hepatic renal toxicities vulnerable individuals. trials real-world studies needed confirm clinical benefits heterogeneous population

Language: Английский

Citations

6
2023 Clinical Practice Guidelines for Diabetes DOI Open Access
Min Kyong Moon

Journal of Korean Diabetes, Journal Year: 2023, Volume and Issue: 24(3), P. 120 - 126

Published: Sept. 30, 2023

The Committee on Clinical Practice Guidelines of the Korean Diabetes Association updated previous clinical practice guidelines for adults with diabetes and prediabetes published eighth edition in May 2023. We performed a comprehensive systematic review recent trials evidence suitable population that could be applicable to real-world practice. These were developed enable all healthcare providers including physicians, experts, certified educators nationwide best care individuals setting. recommendations screening, medical nutrition therapy, pharmacologic therapy type 2 diabetes, obesity, hypertension, lipid management revised updated. use real-time continuous glucose monitoring (CGM) devices was recommended 1 treated multiple insulin injections, additional CGM metrics added blood control target.

Language: Английский

Citations

12
Fenofibrate’s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study DOI Creative Commons
Sangmo Hong, Kyung‐Soo Kim, Kyungdo Han

et al.

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: July 18, 2024

Abstract Background The beneficial effects of fenofibrate on atherosclerotic cardiovascular disease (ASCVD) outcomes in patients with diabetes and statin treatment are unclear. We investigated the all-cause mortality ASCVD diabetes, high triglyceride (TG) levels treatment. Methods performed a nationwide propensity-score matched (1:1) cohort study using data from National Health Information Database Republic Korea 2010 to 2017. included 110,723 individuals TG ≥ 150 mg/dL, no prior diagnoses who used statins fenofibrate, an equal number similar alone (control group). newly diagnosed myocardial infarction (MI), stroke, both (MI and/or stroke), mortality. Results Over mean 4.03-year follow-up period, hazard ratios (HR) for group comparison control were 0.878 [95% confidence interval (CI) 0.827–0.933] MI, 0.901 (95% CI 0.848–0.957) 0.897 0.858–0.937) MI 0.716 0.685–0.749) death. These consistent subgroup 150–199 mg/dL but differed according low-density lipoprotein cholesterol (LDL-C) levels. Conclusion In this involving risk death was significantly lower use conjunction compared alone. However, finding significant only relatively LDL-C Graphical

Language: Английский

Citations

4
Atherosclerotic Cardiovascular Disease Risk Prediction Models in China, Japan, and Korea DOI Creative Commons
Patricia K. Nguyen, Dong Zhao, Tomonori Okamura

et al.

JACC Asia, Journal Year: 2025, Volume and Issue: 5(3), P. 333 - 349

Published: March 1, 2025

The management of atherosclerotic cardiovascular disease (ASCVD) in the United States is currently based upon large epidemiological studies primarily non-Hispanic White subjects. Although this strategy provides a uniform approach that simpler to implement, it may result inappropriately targeting certain Asian populations for treatment on inaccurate ASCVD risk estimation. In state-of-the-art review, we detail similarities and differences prevalence its factors among Chinese, Japanese, Korean people living their native countries. We highlight limitations current calculators when applied East immigrants summarize stratification approaches China, Japan, Korea. Our review underscores need disaggregate registry, cohort, clinical trial data by subgroups, actively engage these research, initiate better define States.

Language: Английский

Citations

0
Clinical Characteristics of Patients With Statin Discontinuation in Korea: A Nationwide Population-Based Study DOI Creative Commons
Kyung‐Soo Kim, Sangmo Hong, Kyungdo Han

et al.

Journal of Lipid and Atherosclerosis, Journal Year: 2024, Volume and Issue: 13(1), P. 41 - 41

Published: Jan. 1, 2024

To investigate the clinical characteristics of patients with statin discontinuation in Korea, using a nationwide database.

Language: Английский

Citations

2
Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT DOI Creative Commons
Eu Jeong Ku,

Bongseong Kim,

Kyungdo Han

et al.

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: Sept. 3, 2024

Abstract Background The potential preventive effect of fenofibrate on lower extremity amputation (LEA) and peripheral arterial disease (PAD) in patients with type 2 diabetes (T2D) is not fully elucidated. Methods We selected adult ≥ 20 years age T2D from the Korean National Health Insurance Service Database (2009–2012). users were matched a 1:4 ratio non-users using propensity scores (PS). outcome variables composite LEA PAD individual components. risks outcomes implemented as hazard (HR) 95% confidence intervals (CI). For safety issues, acute kidney injury, rhabdomyolysis resulting hospitalization analyzed. Results A total 114,920 was included analysis median follow-up duration 7.6 (22,984 91,936 for user non-user groups, respectively). After PS matching, both groups well balanced. group associated significantly (HR 0.81; CI 0.70–0.94), 0.76; 0.60–0.96), 0.68–0.96). risk rhabdomyolysis, or these events showed no significant difference between two groups. Subgroup analyses revealed consistent benefits across genders, baseline lipid profiles. Conclusions This nationwide population-based retrospective observational study suggests that can prevent who are statin therapy.

Language: Английский

Citations

2
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study DOI
Nam Hoon Kim, Ji Yoon Kim, Jimi Choi

et al.

European Heart Journal - Cardiovascular Pharmacotherapy, Journal Year: 2023, Volume and Issue: 10(2), P. 118 - 127

Published: Nov. 28, 2023

Omega-3 fatty acids and fenofibrates have shown some beneficial cardiovascular effects; however, their efficacy has not been compared. This study aimed to compare the effectiveness of currently available omega-3 fenofibrate for reducing major adverse events (MACE). From a nationwide population-based cohort in South Korea (2008-2019), individuals with metabolic syndrome (≥30 years) who received statin those receiving were matched by propensity score (n = 39 165 both groups). The primary outcome was MACE, including ischaemic heart disease (IHD), stroke (IS), death from causes. risk MACE lower [hazard ratio (HR), 0.79; 95% confidence interval (CI), 0.74-0.83] group than acid group. Fenofibrate associated incidence IHD (HR, 0.72; CI, 0.67-0.77) hospitalization failure 0.90; 0.82-0.97), but IS 0.81-1.00) nor causes 1.07; 0.97-1.17). effect compared prominent patients preexisting atherosclerotic doses (≤2 g per day). In real-world setting, use low-dose when added statins people syndrome.

Language: Английский

Citations

4